SEDAT ABUŞOĞLU, Ali ÜNLÜ, Hüseyin Tuğrul ÇELİK, Alpaslan TANER, Mehmet KAYRAK, MEHMET ALKILIÇ HORASANI ÖÇ

Koroner kalp hastalarında asimetrik dimetil arjinin düzeyleri ve dimetilarjinin dimetilamino hidrolaz enziminin genetic polimorfizmi

Amaç: Koroner kalp hastal ı ğ ı olan bireylerde genetik olarak polimorfizm olmas ı kardiyovasküler olaylara yatk ı nl ı ğ ı arttı rabilir. Dimetilarjinin Dimetilamino Hidrolaz (DDAH) enziminde bu genetik de ğ iş imin saptanmas ı ile bu hastal ı k grubunda daha ileri tedavi protokolleri geliştirilmesine katk ı sa ğ lamak için koroner kalp hastalar ı nda Asimetrik Dimetil Arjinin (ADMA) seviyeleri ve DDAH 1 (E.C. 3.5.3.18) enziminin T87M mutasyonu incelendi. Materyal ve Metot: Konya bölgesinde ya şayan 50 koroner kalp hastası ve 50 kontrol bireyi çal ı şmaya dahil edilmiştir. Serum örneklerinden ADMA yüksek performansl ı s ı vı kromatografisi, tam kan örneklerinden izole edilen DNA örneklerinden DDAH 1 T87M mutasyonu PCR yöntemi ile çal ı şı ld ı . Bulgular: ADMA düzeyleri hasta grubunda kontrol grubuna k ı yasla anlaml ı olarak yüksek bulunmu ş olup Arjinin/ADMA oranlar ı nda istatistiksel olarak bir farkl ı l ı k gözlenmemiş tir (Sı ras ı yla p

Investigation of the (DDAH1) T87M mutation of dimethylarginine dimethylaminohydrolase (DDAH E.C. 3.5.3.18) (DDAH 1) enzyme and the levels of asymmetric dimethylarginine (ADMA) in patients with coronary heart disease

Background: Genetic polymorphism may enhance the predisposition to cardiovascular events in patients with coronary heart disease (CHD). The aim of this study is to contribute further treatment protocol development via investigation serum ADMA levels and dimethylarginine dimethylaminohydrolase DDAH 1 (E.C. 3.5.3.18) T87M mutation of CHD patients. Material and Methods: 50 CHD patients and 50 healthy volunteers from Konya region were included to this study. Serum ADMA levels were analyzed by high performance liquid chromatograpy. DDAH (E.C. 3.5.3.18) T87M mutation were determined by PCR from extracted whole blood DNA samples. Results: ADMA levels were significantly higher in patient group compared to control group and there was no statistically diffference between groups for Arginine / ADMA ratio (p<0.001, p=0.08 respectively). Triglyceride levels were significantly higher in patient group compared to control group (p=0.033) and HDL- cholesterol levels were significantly lower in patient group compared to control group (p<0.001). In DDAH 1 T87M polymorphism gene analysis, there was only one heterozygote patient, the other participiants were wildtype. Conclusions: Polymorphism studies with wider population and detailed investigation of risk factors in these polymorphic subjects will contribute to ensure the role of high ADMA levels in cardiovascular diseases.

PDF

___

1. Murray CJ, Lopez AD. Global mortality disability and the contribution of risk factors: Global Burden of Disease study. Lancet 1997;349:36-42.
2. Ross R. The pathogenesis of atherosclerosis. NEJM 1986;314:488-512.
3. Tousoulis D, Davies G, Stefanadis C, Toutouzas P, Ambrose JA. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 2003;89:93-7.
4. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the centers for disease control and prevention and the american heart association. Circulation 2003;107:499511.
5. Tran CT, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl 2003; 4:3340.
6. Weidinger FF, McLenachan JM, Cybulsky MI, et al. Persistent dysfunction of regenerated endothelium following balloon angioplasty of rabbit iliac artery. Circulation 1990;81:166779.
7. Masuda H, Goto M, Tamaoki S, Azuma H. Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxaninduced hyperglycaemia. Br J Pharmacol 1999;126:2118.
8. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999;99: 11416.
9. McDermott JR. Studies on the catabolism of NG-methylarginine, NG, N_G dimethylarginine and NG,NG-dimethylarginine. Biochem J 1976;154: 17984.
10. Murray-Rust J, Leiper J, McAlister M, et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol. 2001;8:67983.
11. Pankaj S, Paul B. Candidate Gene-Based Studies Still Have Value in A World Dominated By Whole Genome Approaches. Circ Res 2010;106:1019- 21.
12. Hasegawa K, Wakino S, Tatematsu S, et al. Role Of Asymmetric Dimethylarginine İn Vascular Injury İn Transgenic Mice Overexpressing Dimethylarginie Dimethylaminohydrolase 2. Circulation Research 2007; 101:2-10.
13. Chen BM, Xia LW, Zhao RQ. Determination ofNG,NG dimethylarginine in human plasma by highperformanceliquid chromatography. J Chromatogr B 1997;692:467-71.
14. Stühlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction induced by hyperhomocysteinemia: Role of ADMA. Circulation 2003;108:9338.
15. Leiper JM, Santa Maria J, Chubb A, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology to microbial arginine deiminases. Biochem J 1999;343:209 14.
16. Böger RH, Cooke JP, Vallance P. ADMA: an emerging cardiovascular risk factor. Vasc Med 2005;10:12.
17. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005;97:53-9.
18. Bae SW, Stühlinger MC, Yoo HS, et al. Plasma Asymmetric Dimethylarginine Concentrations in Newly DiagnosedPatients With Acute Myocardial Infarction or Unstable Angina Pectoris During Two Weeks of Medical Treatment. Am J Cardiol 2005;95:72933.
19. Mark FM. Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine-an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction. Medical Hypotheses 2004;63:699708.
20. Vallance P, Leiper J. Cardiovascular Biology of the Asymmetric Dimethylarginine: Dimethylarginine Dimethylaminohydrolase Pathway. Arterioscler Thromb Vasc Biol 2004;24:1023-30.
21. Zoccali C, Mallamaci F, Tripepi G. Novel Cardiovascular Risk Factors in End-Stage Renal Disease. Journal of the American Society of Nephrology 2004;15:7780.
22. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima- media thickness in predicting clinical coronary events. Ann Intern Med 1998;128:2629.
23. Kielstein JT, Böger RH, Bode-Böger SM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. J AmSoc Nephrol 1999;10:594600.
24. Böger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000;87:99105.
25. Yu XJ, Li YJ, Xiong Y. Increase of an endogenous inhibitor of nitric oxide synthesis in serum of high cholesterol fed rabbits. Life Sci 1994;54:753-8.
26. Päivä H, Laakso J, Ruokonen I, ,et al. Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism 2003;52:303-7.
27. Trocha M, Szuba A, Merwid-Lad A, et al. Effect of selected drugs on plasma asymmetric dimethylarginine (ADMA) levels. Pharmazie 2010;65: 562-71.
28. Selcuk MT, Selcuk H, Temizhan A, et al. Asymmetric dimethylarginine plasma concentrations and L arginine/asymmetric dimethylarginine ratio in patients with slow coronary flow. Coron Artery Dis 2007;18:545-51.
29. Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002;106:98792.
30. Leiper J, Nandi M, Torondel B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007;13:198203.
31. Wang D, Gill PS, Chabrashvili T, et al. Isoform-specific regulation by N(G),N(G)- dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res 2007;101:62735.
32. Maas R, Erdmann J, Lüneburg N, et al. Polymorphisms in the promoter region of the dimethylarginine dimethylaminohydrolase 2 gene are associated with prevalence of hypertension. Pharmacol. Res 2009;60:488 93.
33. Ding H, Wu B, Wang H, et al. A Novel Loss-of-Function DDAH1 Promoter Polymorphism Is Associated With Increased Susceptibility to Thrombosis Stroke and Coronary Heart Disease. Circulation Research 2010;106:1145-52.
34. Jones LC, Tran CT, Leiper JM, Hingorani AD, Vallance P. Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. Biochem Biophys Res Commun 2003;310:83643.
35. Arı H, Arı S, Tiryakio ğ lu H, Huysal K, Koca V, Bozat T. Koroner Kollateral Geli şimine Plazma Asimetrik Dimetilarjinin Düzeylerinin Etkisi. Turkiye Klinikleri J Cardiovasc Sci 2009;21:226-32.